Research Project 1 (RP1) builds on the progress and success of Projects 1 and 2 in ICMIC-2. Our hypothesis is that both constitutive and PSMA-activated reporter gene imaging of PSMA directed T cell targeting, distribution and persistence can be performed concurrently in patients with castrate resistant prostate cancer. The central theme of this proposal is consistent with our ICMIC:

Public Health Relevance

Project 1 involves a phase 1 clinical study to test whether genetically altered, PSMA directed, T cells can be monitored by non-invasive Positron Emission Tomography (PET) imaging, and whether the imaging results can provide an early indication of treatment response (or failure) in patients with castrate resistant prostate cancer. In parallel, preclinical imaging studies will evaluate the effect of an abnormal tumor microenvironment and the effect of tumor PSMA expression levels on: 1) PSMA-directed T cell targeting, activation and persistence, and on 2) the efficacy of tumor-modulated, PSMA-directed T cell therapy. Importantly, these imaging studies could be readily translated to clinic and serve as a model to study other cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086438-13
Application #
8567119
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$236,851
Indirect Cost
$107,193
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Cheal, Sarah M; Xu, Hong; Guo, Hong-fen et al. (2014) Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 13:1803-12
de Biasi, Andreas R; Villena-Vargas, Jonathan; Adusumilli, Prasad S (2014) Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20:5384-91
Vargas, Hebert Alberto; Wassberg, Cecilia; Fox, Josef J et al. (2014) Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 271:220-9
Adusumilli, Prasad S (2014) Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma. Cancer 120:3268-71
Eguchi, Takashi; Kadota, Kyuichi; Park, Bernard J et al. (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210-22
Zhang, Hanwen; Huang, Ruimin; Pillarsetty, NagaVaraKishore et al. (2014) Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging 41:322-32
Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94
Zhang, Hanwen; Huang, Ruimin; Cheung, Nai-Kong V et al. (2014) Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res 20:2182-91
Beattie, Bradley J; Pentlow, Keith S; O'Donoghue, Joseph et al. (2014) A recommendation for revised dose calibrator measurement procedures for 89Zr and 124I. PLoS One 9:e106868
Lee, Ming-Ching; Buitrago, Daniel H; Kadota, Kyuichi et al. (2014) Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. Lung Cancer Manag 3:245-253

Showing the most recent 10 out of 119 publications